Fluticasone furoate

Fluticasone furoate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	C for Intranasal;
Routes of; administration	Intranasal
ATC code	R01AD12 (WHO) R03BA09 (WHO);
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal; Hepatic (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Renal
Identifiers
	IUPAC name (6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate;
CAS Number	80474-14-2;
PubChem CID	9854489;
DrugBank	DB00588;
ChemSpider	8030195;
UNII	JS86977WNV;
ChEBI	CHEBI:74899;
ChEMBL	ChEMBL1676;
CompTox Dashboard (EPA)	DTXSID401024827 DTXSID60228586, DTXSID401024827 ;
ECHA InfoCard	100.158.130
Chemical and physical data
Formula	C27H29F3O6S
Molar mass	538.576 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F;
	InChI InChI=1S/C27H29F3O6S/c1-14-9-16-17-11-19(29)18-10-15(31)6-7-24(18,2)26(17,30)21(32)12-25(16,3)27(14,23(34)37-13-28)36-22(33)20-5-4-8-35-20/h4-8,10,14,16-17,19,21,32H,9,11-13H2,1-3H3/t14-,16+,17+,19+,21+,24+,25+,26+,27+/m1/s1; Key:XTULMSXFIHGYFS-VLSRWLAYSA-N;

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, South America, Mexico, Israel, and South Korea) for the treatment of allergic rhinitis administered by a nasal spray.^[1]

The combination drug fluticasone furoate/vilanterol, marketed as Breo Ellipta (US, Canada) and Relvar Ellipta (UK), is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.^[2] As of 2015, it is also approved for the treatment of asthma. ^[3]

References

^ Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.
^ "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.
^ "BREO® ELLIPTA® 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)" (PDF).

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[pmid19571596-1] Bruni FM, De Luca G, Venturoli V, Boner AL (2009). "Intranasal corticosteroids and adrenal suppression". Neuroimmunomodulation. 16 (5): 353–62. doi:10.1159/000216193. PMID 19571596.

[2] "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. May 10, 2013.

[3] "BREO® ELLIPTA® 100/25 (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder)" (PDF).

[1]

[2]

[3]

See also

References